Monarch Capital Management Inc. Has $3.66 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Monarch Capital Management Inc. lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 34,571 shares of the medical equipment provider’s stock after selling 100 shares during the period. Monarch Capital Management Inc.’s holdings in Zimmer Biomet were worth $3,660,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Dunhill Financial LLC raised its holdings in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet during the third quarter valued at approximately $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet in the third quarter valued at $31,000. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet in the third quarter valued at $35,000. Finally, Quarry LP bought a new position in Zimmer Biomet in the second quarter worth $53,000. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ZBH. Raymond James dropped their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Royal Bank of Canada increased their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, BTIG Research cut their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $123.33.

Zimmer Biomet Price Performance

ZBH opened at $109.65 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The stock has a market capitalization of $21.83 billion, a P/E ratio of 20.85, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. The company’s 50 day simple moving average is $107.84 and its 200-day simple moving average is $107.99. Zimmer Biomet Holdings, Inc. has a one year low of $100.67 and a one year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period last year, the company earned $1.65 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.